Evidence map›Paper›PMID 21160498›Full record

ArticleThe Journal of investigative dermatology2011

Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis.

Dov Hershkovitz, Yonit Gross, Sagi Nahum, Shiran Yehezkel, Ofer Sarig, Jouni Uitto, Eli Sprecher

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. ConstitutionalHaematologica · 2018
    Trial
  4. Article
  5. A De Novo Mutation (c.2423A>G) inHuman mutation · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Bilateral brachial artery infiltration by tumoral calcinosis: A case report.Acta orthopaedica et traumatologica turcica · 2021
    Article
  17. Review
  18. Article
  19. Article
  20. Frontiers in immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dov HershkovitzInstitute of Pathology, Rambam Health Care Campus, Haifa, Israel.
Yonit Gross
Sagi Nahum
Shiran Yehezkel
Ofer Sarig
Jouni Uitto
Eli Sprecher
Technion – Israel Institute of Technology · ILTel Aviv Sourasky Medical Center · ILThomas Jefferson University · US

Funding

Molecular Genetics of Familial Tumoral CalcinosisR01AR052627 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI UITTO, JOUNI · 2005 to 2009
$1.6M
NIAMS NIH HHS R01 AR052627
6 · The paper itself

Abstract

Dystrophic cutaneous calcinosis is associated with disorders as common as autoimmune diseases and cancer. To get insight into the pathogenesis of this poorly understood process, we studied the function of SAMD9, a protein of unknown function, recently shown to be deficient in a hereditary form of dystrophic calcification in the skin, known as normophosphatemic familial tumoral calcinosis (NFTC). Consistent with the fact that in NFTC severe inflammatory manifestations always precede cutaneous calcinosis, we found out that SAMD9 is tightly regulated by interferon-γ (IFN-γ). In addition, the SAMD9 promoter was also found to respond strongly to IFN-γ in a luciferase reporter assay. Of interest, we identified a critical 30-bp fragment upstream to the SAMD9 transcription initiation site responsible for driving most of the gene expression. Bioinformatic analysis suggested that SAMD9 function involves interaction with additional protein(s). Using the Ras recruitment system assay and confirmatory immunoprecipitation, we demonstrated that SAMD9 interacts with RGL2. To study the biological importance of this interaction, we assessed the effect of RNA interference-mediated downregulation of this pair of proteins in various cell lines. We found out that downregulation of any of the two protein partners caused increased expression of EGR1, a transcription factor with a known role in the regulation of tissue calcification, inflammation, and cell migration. Supporting the physiological relevance of these data, EGR1 levels were also upregulated in a fibroblast cell line derived from an NFTC patient. In conclusion, our data indicate that SAMD9, an IFN-γ-responsive protein, interacts with RGL2 to diminish the expression of EGR1, a protein of direct relevance to the pathogenesis of ectopic calcification and inflammation.

Indexed as

CalcinosisCells, CulturedEarly Growth Response Protein 1FibroblastsGuanine Nucleotide Exchange FactorsHumansInterferon-gammaIntracellular Signaling Peptides and ProteinsProteinsrab GTP-Binding ProteinsSignal TransductionSkin DiseasesEarly Growth Response Protein 1EGR1 protein, humanGuanine Nucleotide Exchange FactorsInterferon-gammaIntracellular Signaling Peptides and ProteinsProteinsrab GTP-Binding ProteinsRGL2 protein, humanSAMD9 protein, human

Identifiers

PMID21160498
PMCPMC3169306
OpenAlexW2024114809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.